Equibles does not estimate personal net worth.
Get an email with a short summary when Legend Biotech Corp publishes a filing, an earnings call transcript or a press release.
Get LEGN alertsLori Macomber is recorded as CFO at Legend Biotech Corp (LEGN) and CFO at Karyopharm Therapeutics Inc. (KPTI). Karyopharm Therapeutics Inc. reported in an 8-K filed January 2, 2025 that Lori Macomber was appointed Executive Vice President, Chief Financial Officer and Treasurer, effective January 3, 2025. Lori Macomber has spoken on 8 earnings calls across 2 companies, most recently for Karyopharm Therapeutics Inc. on August 13, 2026. Those appearances were for Karyopharm Therapeutics Inc. (KPTI) and Legend Biotech Corp (LEGN). Karyopharm Therapeutics Inc. is classified in the Biotechnology industry within the Healthcare sector. Legend Biotech Corp is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Karyopharm Therapeutics Inc. includes Richard Paulson (CEO and Board Member), Senior Clinical (CEO), Michael Mano (General Counsel) and 7 others.
“On December 12, 2024, the Board of Directors (“Board”) of Karyopharm Therapeutics Inc. (the “Company”) approved, and the Company publicly announced on January 2, 2025, the election of Lori Macomber, age 54, to the position of Executive Vice President, Chief Financial Officer and Treasurer of the Company, effective January 3, 2025.”
“Turning to slide 33, I will focus on our second quarter financial performance, our financial outlook, and the actions we're taking to support the important milestones Richard outlined.”
“I will focus on the key highlights from our first quarter financial performance and how those results position us relative to our full year expectations. Starting with revenue, total revenue for the first quarter was $35.1 million compared to $30 million in the prior year period.”
“Total revenue for the fourth quarter of 2025 was $34.1 million, an increase of 11.8% compared to the fourth quarter of 2024. For the year, total revenue was $146.1 million, a slight increase from 2024.”
“Since we issued a press release earlier today with the full financial results, I will focus on the highlights and reviewing our guidance for 2025 on Slide 21. Total revenue for the third quarter of 2025 was $44 million, an increase of 13.4% compared to $38.8 million in the third quarter of 2024.”
“As Ying mentioned, we generated approximately $286 million in total net sales for CARVYKTI during the third quarter, an increase of 87.6% year-over-year. As a reminder, we share equally in all profits and losses of CARVYKTI ex-China with our partner, Janssen.”
Biotechnology · Healthcare
CFO
LEGN
Biotechnology · Healthcare
CFO
